Mercedes Dalurzo
Hospital Italiano de Buenos Aires
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mercedes Dalurzo.
Human Pathology | 2010
María José Carlini; Mercedes Dalurzo; José Lastiri; David Smith; Bartolomé Vasallo; Lydia Puricelli; Lilia Lauria de Cidre
The impact of interstitial inflammatory cells, such as mast cells, and angiogenesis on the prognosis of cancer patients has been reported in many solid tumors, although there is disagreement about their role. We undertook a retrospective study with tissue samples from 65 patients with stage I and II non-small cell lung cancer to assess the clinical pathologic role and prognostic significance of mast cells. Mast cell phenotypes were identified by immunohistochemistry for tryptase and chymase. In addition, we identified microvessels using the endothelial marker CD34. Mast cell and microvessel density was quantified by assessing immunopositive cells in the intratumoral and peritumoral zones of tumor specimens. Both mast cell and microvessel density was higher in the peritumoral zone than the intratumoral zone (P <or= .05). A positive correlation between mast cell (tryptase-chymase phenotype) and microvessel densities was observed in the intratumoral zone (P <or= .05), supporting the involvement of mast cells in the angiogenic process. Regarding survival, a subset of stage I patients had a worse prognosis at five years when low mast cell (tryptase-chymase phenotype) density was found in the peritumoral zone (median survival in months [range]: 27 [1-60] versus 46 [1-60]). Multivariate Cox analysis indicated that this parameter may be an independent prognostic factor (P <or= .05) useful for selecting candidates for earlier treatment.
Journal of Clinical Pathology | 2013
Maxwell L. Smith; Mercedes Dalurzo; Prasad M. Panse; James M. Parish; Kevin O. Leslie
Pulmonary fibrosis in surgical lung biopsies is said to have a ‘usual interstitial pneumonia-pattern’ (UIP-pattern) of disease when scarring of the parenchyma is present in a patchy, ‘temporally heterogeneous’ distribution. These biopsies are one of the more common non-neoplastic specimens surgical pathologists encounter and often pose a number of challenges. UIP is the expected histopathological pattern in patients with clinical idiopathic pulmonary fibrosis (IPF), but the UIP-pattern can be seen in other conditions on occasion. Most important among these are the rheumatic interstitial lung diseases (RILD) and chronic hypersensitivity pneumonitis (CHrHP). Because theses entities have different mechanisms of injury, approach to therapy, and expected clinical progression, it is imperative for the surgical pathologist to correctly classify them. Taken in isolation, the UIP-pattern seen in patients with IPF may appear to overlap with that of RILD and CHrHP, at least when using the broadest definition of this term (patchy fibrosis). However, important distinguishing features are nearly always present in our experience, and the addition of a multidisciplinary approach will often resolve the critical differences between these diseases. In this manuscript, we review the distinguishing clinical, radiologic and histopathological features of UIP of IPF, RILD and CHrHP, based, in part, on the existing literature, but also lessons learned from a busy lung biopsy consultation practice.
The American Journal of Surgical Pathology | 2014
Kirtee Raparia; James Ketterer; Mercedes Dalurzo; Yu Hui Chang; Thomas V. Colby; Kevin O. Leslie
Malignant tumors in the lung (both primary and metastatic) rarely may be associated with markedly discohesive tumor cells, resulting in airspace filling reminiscent of “desquamative interstitial pneumonia” (DIP) on histopathology evaluation. A peculiar aspect of this growth pattern is the relatively bland appearance of the tumor cells, in many cases simulating benign alveolar macrophages at scanning magnification. We searched the Charles Carrington Memorial consultation files in the Department of Laboratory Medicine and Pathology at Mayo Clinic Arizona for instances of malignant tumors in lung simulating DIP, from 1992 to 2011. We identified 7 cases involving transbronchial biopsies, needle core samples, or resected lung specimens. Clinical, histopathologic, and immunohistochemical analyses of these 7 patients were performed, including detailed morphometric analysis of the individual tumor cells using calibrated measurement tools on digital images. We compared the results with those of a control group of 4 patients with benign DIP-macrophage reactions in smoking-related lung disease. The study group comprised 5 male and 2 female patients, 48 to 86 years in age (median: 67 y). The radiologic findings included lobar consolidation, localized ground-glass opacities, and 1 or more nodules. None of the patients had typical bilateral infiltrates of DIP. Microscopically, the lung parenchyma was dominated by the presence of prominent tumor cells filling alveolar spaces. Four patients had primary lung carcinoma (adenocarcinoma), whereas 3 had metastases from other sites, including a melanoma. Immunohistochemical staining studies were performed on 6 of 7 cases to establish the diagnosis. Nuclear diameter, cytoplasmic diameter, and nuclear/cytoplasmic (N/C) ratios in patient and control groups were compared using the Wilcoxon rank sum test. No significant difference in the diameters of nucleus and cytoplasm between cases and control groups (P=0.3447 and 0.7055, respectively) was seen, and only a marginally significant difference in N/C ratios (P=0.0890) was seen. A more complex analysis, generalized estimating equation analysis, showed a significant difference in N/C ratio between the 2 groups (P=0.0278). A “DIP-growth pattern” of malignant tumors in the lung is presented. Although the N/C ratio differences approached statistical significance when compared with controls, the key to diagnosis is the recognition of the malignant cytology of the tumor nuclei. Immunohistochemical studies (keratin or other markers) are helpful in establishing an accurate diagnosis in this setting.
Oncology Reports | 2010
Laura V. Mauro; Mercedes Dalurzo; María José Carlini; David D. Smith; Myriam Nuñez; Marina Simian; José Lastiri; Bartolomé Vasallo; Elisa Bal de Kier Joffé; María Guadalupe Pallotta; Lydia Puricelli
Clinical & Experimental Metastasis | 2013
Paula Vazquez; María José Carlini; María Cecilia Daroqui; Lucas L. Colombo; Mercedes Dalurzo; David Smith; Julieta Grasselli; María Guadalupe Pallotta; Marcelo Ehrlich; Elisa Bal de Kier Joffé; Lydia Puricelli
Medicina-buenos Aires | 2008
Laura V. Mauro; Mercedes Dalurzo; David Smith; José Lastiri; Bartolomé Vasallo; Elisa Bal de Kier Joffe; María Guadalupe Pallotta; Lydia Puricelli
Medicina-buenos Aires | 2008
Laura V. Mauro; Mercedes Dalurzo; David Smith; José Lastiri; Bartolomé Vasallo; Joffei Eb; María Guadalupe Pallotta; Puricelli L
Journal of Thoracic Oncology | 2017
Mercedes Dalurzo
Journal of Thoracic Oncology | 2017
Paola X. De La Iglesia; Mercedes Dalurzo
Journal of Thoracic Oncology | 2017
Jose Minatta; Lorena Lupinacci; Mercedes Dalurzo; Esteban Mocetti; José Lastiri; Maria J. Labanca